Literature DB >> 33566014

X-ray phase contrast tomography for the investigation of amyotrophic lateral sclerosis.

Ginevra Begani Provinciali1, Nicola Pieroni1, Inna Bukreeva1, Michela Fratini1, Lorenzo Massimi2, Laura Maugeri3, Francesca Palermo1, Fabrizio Bardelli1, Alberto Mittone4, Alberto Bravin4, Giuseppe Gigli5, Francesco Gentile6, Andrea Fossaghi6, Nilo Riva6, Angelo Quattrini6, Alessia Cedola1.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder affecting motor neurons. Pre-clinical studies drive the development of animal models that well mimic ALS disorder and enable both the dissection of disease processes and an early assessment of therapy efficacy. A comprehensive knowledge of neuronal and vascular lesions in the brain and spinal cord is an essential factor to understand the development of the disease. Spatial resolution and bidimensional imaging are important drawbacks limiting current neuroimaging tools, while neuropathology relies on protocols that may alter tissue chemistry and structure. In contrast, recent ex vivo studies in mice demonstrated that X-ray phase-contrast tomography enables study of the 3D distribution of both vasculature and neuronal networks, without sample sectioning or use of staining. Here we present our findings on ex vivo SOD1G93A ALS mice spinal cord at a micrometric scale. An unprecedented direct quantification of neuro-vascular alterations at different stages of the disease is shown. open access.

Entities:  

Keywords:  ALS; X-ray phase contrast tomography; spinal cord

Year:  2020        PMID: 33566014     DOI: 10.1107/S1600577520006785

Source DB:  PubMed          Journal:  J Synchrotron Radiat        ISSN: 0909-0495            Impact factor:   2.616


  1 in total

1.  X-ray Phase Contrast Tomography Serves Preclinical Investigation of Neurodegenerative Diseases.

Authors:  Francesca Palermo; Nicola Pieroni; Laura Maugeri; Ginevra Begani Provinciali; Alessia Sanna; Lorenzo Massimi; Maura Catalano; Margie P Olbinado; Inna Bukreeva; Michela Fratini; Antonio Uccelli; Giuseppe Gigli; Nicole Kerlero de Rosbo; Claudia Balducci; Alessia Cedola
Journal:  Front Neurosci       Date:  2020-11-09       Impact factor: 4.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.